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Abstract
Background: We have recently developed a new technique for quantitatively measuring protein-bound 3-nitrotyrosine 
(3-NT), a footprint of nitrosative stress, utilizing high-performance liquid chromatography with an electrochemical detection 
(HPLC-ECD) system. Using this system, we showed that 3-NT formation was upregulated in the sputum of both COPD 
and asthmatic patients. However, in order to improve the accuracy of the measurement system, We have to resolve some 
problems which were the inﬂ  uence of free amino acid form of 3-NT and of salivary contamination.
Objectives: We initially investigated the amount of the free amino acid form of 3-NT in induced sputum and compared 
with that of protein-bound 3-NT. Next, we evaluated the concentration of protein-bound 3-NT in saliva and compared with 
that in induced sputum by means of HPLC-ECD.
Methods: Five male COPD patients were enrolled. Induced sputum and saliva were obtained from the patients. The free 
amino acid form of 3-NT in sputum and saliva was measured by HPLC-ECD, and the protein-bound 3-NT and tyrosine in 
sputum and saliva were enzymatically hydrolyzed by Streptomyces griseus Pronase and measured for the protein hydroly-
sate by HPLC-ECD.
Results: The mean value of the amount of protein-bound 3-NT was 65.0 fmol (31.2 to 106.4 fmol). On the other hand, the 
amount of the free amino acid form of 3-NT was under the detection limit (<10 fmol). The levels of both 3-NT (sputum: 
0.55 ± 0.15 pmol/ml, saliva: 0.02 ± 0.01 pmol/ml, p < 0.01) and tyrosine (sputum: 0.81 ± 0.43 µmol/ml, saliva: 0.07 ± 0.04 
µmol/ml, p < 0.01) in saliva were signiﬁ  cantly lower than in sputum. The percentage of 3-NT in saliva to that in sputum 
was about 3.1%, and that of tyrosine was about 9.0%. 
Conclusion: The free amino acid form of 3-NT does not affect the measurement of protein-bound 3-NT. Furthermore, the 
inﬂ  uence of salivary contamination on the measurement of protein-bound 3-NT in induced sputum by means of HPLC-ECD 
was very small and could be negligible.
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Introduction
Inﬂ  ammation of the airways seems to plays an important role in the pathogenesis of chronic obstructive 
pulmonary disease (COPD) (National Institutes of Health, Updated 2005; Barnes, 2002). However, the 
pathogenesis has not yet been fully elucidated. Reactive nitrogen species (RNS) may be involved in 
the pathophysiology of the inﬂ  ammatory process in COPD (Ichinose et al. 2000; Barnes, 2000). RNS 
are formed from the reaction of nitric oxide (NO) and superoxide anion (Beckman et al. 1990), or via 
the H2O2/peroxidase-dependent nitrite oxidation pathway (Eiserich et al. 1998).
The production of RNS was reported to be upregulated in the airways of asthmatic patients (Saleh 
et al. 1998; Hamid et al. 1993). Recently, we reported that the production of RNS was also upregulated in 
the COPD airways based on immunostaining for 3-nitrotyrosine (3-NT), which is a footprint of nitrosa-
tive stress (Ichinose et al. 2000). Since this method was semi-quantitative, we developed a new technique 
for the quantitative measurement of 3-NT which utilizes high-performance liquid chromatography with Analytical Chemistry Insights 2007: 1 2
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an electrochemical detection (HPLC-ECD) system. 
Using this system, we reported that the protein-
bound 3-NT levels were increased in the induced 
sputum of both COPD and asthmatic patients, and 
there was a signiﬁ  cant correlation between 3-NT/
tyrosine value and % predicted forced expiratory 
volume in one second (FEV1) in COPD patients 
but not in asthmatic patients (Sugiura et al. 2004). 
However, there are some problems to be resolved 
to improve the accuracy of the measurement 
system.
We have focused on the measurement of 
protein-bound 3-NT (Sugiura et al. 2004; Hirano 
et al. 2006) because the nitration of tyrosine resi-
dues in various proteins was reported to alter the 
function of the proteins (Beckman et al. 1990; Radi 
et al. 1991; Lipton et al. 1993; Beckman, 1996). 
However, The various biological samples contain 
both protein-bound 3-NT and the free amino acid 
form of 3-NT (Greenacre and Ischiropoulos, 2001), 
and the inﬂ  uence of the amount of the free amino 
acid form of 3-NT on the results of protein-bound 
3-NT has not been assessed.
Furthermore, though the induced sputum tech-
nique by hypertonic saline inhalation that we used 
is an effective and relatively noninvasive method 
for obtaining airway secretions (Pin et al. 1992; 
Fahy et al. 1993), this method may have the disad-
vantage of a considerable and unpredictable level 
of salivary contamination which could inﬂ  uence 
the values of 3-NT in the induced sputum, and this 
issue has not been fully addressed.
Therefore, the aims of this study were to investi-
gate the inﬂ  uence of the free amino acid form of 3-
NT on the measurement of protein-bound 3-NT, and 
to evaluate the inﬂ  uence of saliva on the measure-
ment of protein-bound 3-NT in induced sputum by 
means of HPLC-ECD in COPD patients.
Methods
Study subjects
Five male patients with COPD visiting our hospital 
were recruited in the current study after providing 
written informed consent. All patients were diag-
nosed as COPD and satisﬁ  ed the deﬁ  nition of the 
Global Initiative for Chronic Obstructive Lung 
Disease (National Institutes of Health, Updated 
2005). The study was approved by the local ethics 
committee. The clinical characteristics of these 
subjects are shown in Table 1.
Sputum induction and saliva sampling
Sputum was induced according to the method 
described in previous studies (Pin et al. 1992; 
Hirano et al. 2006). Brieﬂ  y, to prevent the bron-
choconstriction that would be induced by hyper-
tonic saline inhalation, all subjects inhaled salbu-
tamol (400 μg) before sampling. Fifteen minutes 
after salbutamol inhalation, the subjects inhaled 
4% hypertonic saline using an ultrasonic nebulizer 
(UN-701; AICA Co Ltd, Tokyo, Japan). Sputum 
sampling was performed every ﬁ  ve minutes until 
the sputum volume was more than 1.0 ml. In order 
to prevent saliva contamination in the sputum, the 
oral cavity was rinsed out with water, and retained 
saliva was removed by rolling the sputum on dry 
gauze. Saliva was also obtained after sputum 
induction. Over 1.0 ml of saliva was sampled.
Sample processing
Sputum and saliva were immediately and gently 
treated with dithiothreitol (Oxoid Ltd, Basingstoke, 
Hampshire, UK) at 4 times the volume to dissociate 
the disulphide bonds in mucin molecules. The 
mixtures were centrifuged at 790 g for 5 min at 
4°C and the supernatants were obtained. All super-
natants were stored at –80°C until the measurement 
of 3-NT and tyrosine.
Preparation of protein-bound 3-NT, 
tyrosine, and free 3-NT
The protein-bound 3-NT and tyrosine in sputum 
and saliva were measured by the protein hydroly-
sate according to the method reported in the 
previous study (Sugiura et al. 2004). Brieﬂ  y, a 
supernatant sample was centrifuged at 9000 g for 
5 min to remove impurities. The supernatant 
sample was centrifuged again at 9000 g for 30 min 
Table 1. Characteristics of Study Subjects.
Sex (M/F)  5/0
Age (years)  71.6 ± 2.4
Smoking  
current/ex 5/0
pack-year 69.2  ±  20.4
FEV1 (L)  1.72 ± 0.80
FEV1/FVC (%)  45.0 ± 14.5
FEV1%predicted (%)  64.4 ± 29.5
IC (L)  2.83 ± 0.59
Deﬁ  nition of abbreviations: FEV1 = forced expiratory volume in 
one second, FVC = forced vital capacity, IC = inspiratory capacity, 
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with an Ultrafree-MC centrifugal ﬁ  lter (Millipore 
Corp, Bedford, MA, USA) which can filtrate 
proteins of less than 10 kDa. The ﬁ  ltrate was 
prepared for the measurement of the free amino 
acid form of 3-NT, because the presence of protein 
of more than 10 kDa causes an obstruction in the 
HPLC-ECD column. The condensed supernatant 
was enzymatically hydrolyzed to liberate the 3-NT 
and tyrosine residues for the measurement of 
protein-bound 3-NT and tyrosine. Samples were 
mixed with a freshly prepared solution of Strep-
tomyces griseus Pronase (Calbiochem, Darmstadt, 
Germany), which was dialyzed against phosphate 
buffered saline (pH 7.2) before use. The sample 
and pronase solution were mixed in a proportion 
of ﬁ  ve to one in total protein. The pronase-treated 
samples were incubated at 50°C for 18 hours to 
hydrolyze the proteins. The hydrolysate was 
centrifuged at 9000 g with ﬁ  ltration for 30 min 
using an Ultrafree-MC centrifugal ﬁ  lter (10 kDa 
cut off), and then the ﬁ  ltrates were analyzed for 
3-NT and tyrosine by HPLC-ECD. The protein 
concentration was determined by the Bradford 
method (Bradford, 1976).
Quantiﬁ  cation of 3-NT by HPLC-ECD
The sample was subjected to a reverse phase 
column (C18:3 × 150 mm; Eicom, Kyoto, Japan) 
and eluted under isocratic conditions with 100 
mM sodium phosphate buffer (pH 5.0) containing 
5% methanol at a ﬂ  ow rate of 0.5 ml/min. The 
eluate was continuously applied to the analytical 
electrochemical system that consisted of two 
electrochemical cells. The upstream electro-
chemical cell was coulometric and made of porous 
carbon. 3-NT was reduced into 3-aminotyrosine 
on this cell at a reduction potential of –900 mV. 
The downstream cell was amperometric glassy 
carbon to oxidize the 3-aminotyrosine at an oxida-
tion potential of +300 mV. The 3-NT was quanti-
ﬁ  ed by the response at the oxidation cell on the 
basis of a standard curve of electrochemical 
responses as a function of the authentic 3-NT 
(Sigma Chemical Co, St Louis, MO) concentra-
tion. The speciﬁ  city of the detection of the peak 
for 3-NT by this system was conﬁ  rmed according 
to the previous study and the following criteria: 
[1]Comparison of the retention time of the peak 
with that of authentic 3-NT, which is 12.9 min 
under these HPLC-ECD conditions, [2]Disap-
pearance of the peak after treatment of the sample 
with 100 mM sodium hydrosulfate (Na2S2O4) in 
PBS (pH 7.4) for 30 min at 37°C, [3] Nulliﬁ  cation 
of the peak using a reduction potential of 
–600 mV (Sugiura et al. 2004). The values of 
concentration were expressed as those in original 
sputum or saliva.
Quantiﬁ  cation of tyrosine 
by HPLC-ECD
The amount of 3-NT in each sample was standard-
ized by the amount of tyrosine in the same sample, 
which was determined in another HPLC-ECD 
system for tyrosine. The hydrolysate was injected 
into a reverse phase column (4.6 × 150 mm, TSK 
gel ODS-80TS; Tosoh, Tokyo, Japan) and eluted 
to separate tyrosine under isocratic conditions 
with 50 mM sodium acetate buffer (pH 4.7) plus 
5% methanol at a ﬂ  ow rate of 0.8 ml/min. The 
tyrosine peak was detected using an HPLC-ECD 
system (D-7000, Hitachi, Tokyo, Japan) and 
electrochemical detector (NANOSPACE, 
Shiseido, Tokyo, Japan). The retention time of 
tyrosine under these conditions is 4.1 min and 
showed a typical profile of electrochemical 
responses at +600 mV (Sugiura et al. 2004). The 
values of the concentration were expressed as 
those in original sputum or saliva.
Statistical analysis
The data are presented as mean ± SD. Mann-Whit-
ney’s U test was used to compare the concentration 
of 3-NT or tyrosine in sputum and saliva. A p-value 
of less than 0.05 was considered signiﬁ  cant.
Results
Standard curve and detection limit
We examined the dose dependent proﬁ  le of the 
electrochemical response for authentic 3-NT. A 
linear electrochemical response was observed in a 
wide range of authentic 3-NT concentrations 
(10–1000 fmol in absolute amounts). Actually, the 
range of 3-NT in sputum and saliva in this system 
was up to 100 fmol from our preliminary data. The 
detection limit was 10 fmol (Fig. 1).
Protein-bound and free 3-NT
We analyzed the formation of the free amino acid 
form of 3-NT in supernatants of sputum by using 
filtrates obtained with an ultrafiltration tube Analytical Chemistry Insights 2007: 1 4
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(10 kDa cut off). The amounts of protein-bound 
3-NT and the free amino acid form of 3-NT when 
50 µl hydrolysate were injected are shown in 
Fig. 2. The mean value of the amount of protein-
bound 3-NT was 65.0 fmol (31.2 to 106.4 fmol), 
whereas the amount of the free amino acid form 
of 3-NT was under the detection limit (<10 fmol) 
with this system (Fig. 2).
Protein-bound 3-NT and tyrosine in 
sputum and saliva 
In COPD patients, the levels of 3-NT in saliva were 
signiﬁ  cantly lower than those in sputum (sputum: 
0.55 ± 0.15 pmol/ml, saliva: 0.02 ± 0.01 pmol/ml; 
p < 0.01). The levels of tyrosine in saliva were also 
signiﬁ  cantly lower than in sputum (sputum: 0.81 ± 
0.43 micro mol/ml, saliva: 0.07 ± 0.04 micro 
mol/ml; p < 0.01) (Fig. 3). The values of 3-NT and 
tyrosine in saliva were about 3.1% and 9.0% of 
those in sputum, respectively.
Discussion
In the current study, we found that the amount of 
free amino acid form of 3-NT was very small and 
was under the detection limit in this HPLC-ECD 
system, though it could be present in the sputum. 
This suggests that the inﬂ  uence of the free amino 
acid form of 3-NT on the values of protein-bound 
3-NT would be very small and could be negligible. 
Furthermore, we found that the values of 3-NT and 
tyrosine in saliva were 3.1%, 9.0% of those in 
sputum, respectively. 
Tyrosine is one of the amino acids that compose 
proteins. Protein-bound 3-NT and protein-bound 
tyrosine are composed of various proteins, and 
free amino acid forms of 3-NT and of tyrosine 
are present in induced sputum. The free amino 
acid form of 3-NT might affect the measured 
values of protein-bound 3-NT by HPLC-ECD. 
Compared with the amount of protein-bound 
3-NT, which was 65.0 fmol, that of the free amino 
acid form of 3-NT was very small and under the 
Figure 1. Standard curve for 3-nitrotyrosine by high-performance liquid chromatography with electrochemical detection (HPLC-ECD). 
A linear electrochemical response was observed in a wide range of authentic 3-nitrotyrosine concentrations. The detection limit of this HPLC-
ECD system was 10 fmol.
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detection limit (<10 fmol). This suggests that the 
inﬂ  uence of the contamination of free 3-NT would 
be very small.
Salivary contamination in induced sputum 
cannot be avoided completely, but most can be 
removed by gargling and then by rolling the sputum 
samples on dry gauze as much as possible after the 
induction. To reduce the contribution of saliva to 
the induced sputum samples, sputum and saliva 
have been collected separately during sputum 
induction for measuring cytokines (Keatings et al. 
1996) or eosinophil cationic protein (ECP) 
(Gershman et al. 1996). Pin et al. restricted their 
analyses of induced sputum to plugs of mucus 
extracted from the sample, and the volume of the 
contaminating saliva was assumed to be very small 
Figure 3. Concentration of protein-bound 3-nitrotyrosine and protein-bound tyrosine in sputum and saliva. Both the concentrations 
of protein-bound 3-nitrotyrosine and protein-bound tyrosine were signiﬁ  cantly lower in saliva than in sputum. 3-NT: 3-nitrotyrosine. Data are 
presented as mean ± SD.
Figure 2. The levels of protein-bound and the free amino acid form of 3-nitrotyrosine in the hydrolysate from COPD patients. The 
amount of the free amino acid form of 3-nitrotyrosine was under the detection limit (<10 fmol) and much smaller than that of protein-bound 
3-nitrotyrosine. 3-NT: 3-nitrotyrosine.
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in comparison with the volume of sputum (Pin 
et al. 1992). These reports suggest that the contri-
bution of saliva to the measurement values can be 
minimized by various methods.
Examinations of the influence of salivary 
contamination in induced sputum have been 
reported. Fahy et al. (Fahy et al. 1993) reported 
that the amount of ECP in saliva from asthmatic 
subjects was much lower than in paired induced 
sputum samples. They concluded that the principal 
effect of saliva in induced sputum was only that of 
diluting the sample. Dauletbaev et al. (Dauletbaev 
et al. 2001) reported that the glutathione content 
of the saliva was signiﬁ  cantly lower than that in 
the sputum. Sagel et al. (Sagel et al. 2001) reported 
that the salivary IL-8 levels were one-ﬁ  fteenth the 
levels in the induced sputum samples and were, 
therefore, unlikely to signiﬁ  cantly affect the levels 
measured in the sputum. These reports were 
compatible with our data, in which the concentra-
tions of 3-NT and tyrosine in saliva were 3.1% and 
9.0% of those in induced sputum, respectively. 
For the measurement of 3-NT from human 
samples, a large number of studies using antibody-
based methods have been reported. For example, 
immunohistochemical staining of 3-NT has been 
reported in the tissue or ﬂ  uid from inﬂ  amed colonic 
epithelium (Singer et al. 1996), chronic hepatic 
diseases (Cuzzocrea et al. 1998; Garcia-Monzon 
et al. 2000), atherosclerotic plaques (Cromheeke 
et al. 1999), Alzheimer’s disease (Smith et al. 1997) 
and cystic ﬁ  brosis (Morrissey et al. 2002). We also 
measured the 3-NT in induced sputum from COPD 
patients by immunohistochemical staining 
(Ichinose et al. 2000; Hirano et al. 2006), but this 
method is semi-quantitative. Other measurements 
made by employing ELISA assay have been 
reported (Ceriello et al. 2001; Oldreive et al. 2001; 
ter Steege et al. 1998; Banks et al. 1998), but there 
was no rigorous assay validation and the reliability 
was poor because the peroxidase employed in the 
process of ELISA might have stimulated the 
production of 3-NT (Duncan, 2003).
HPLC combined with an electrochemical detec-
tion method is a quantitative method for measuring 
3-NT. Both UV (Crow and Ischiropoulos, 1996) 
and ﬂ  uorescence detection (Kamisaki et al. 1996) 
have been employed, but they were too insensitive. 
Consequently, HPLC-EC systems have been 
commonly employed to measure 3-NT in human 
samples (Crow, 1999; Hensley et al. 1998; Moore 
and Mani, 2002; Shigenaga et al. 1997; Ohshima 
et al. 1999). In these studies, the detection limit of 
3-NT was 0.1 pmol/20 µl injection, but with our 
current HPLC-ECD system the detection limit was 
10 fmol/10 µl injection which was 20 times more 
sensitive than the other reported methods. The 
current HPLC-ECD is thought to be the most 
accurate system for quantifying 3-NT in sputum.
We previously reported that the levels of 3-NT 
were increased in induced sputum from asthma 
and COPD patients by HPLC-ECD (Sugiura et al. 
2004), and that theophylline reduced the levels of 
3-NT in COPD patients (Hirano et al. 2006). Our 
present report supports the precision of the data 
obtained with this HPLC-ECD system.
The presence of co-morbid diseases associated 
with higher protein-bound 3-NT production in 
saliva such as periodontal disease, might inﬂ  uence 
the values of 3-NT in sputum. Further study should 
be necessary to clarify the inﬂ  uence of co-morbid 
diseases in oral cavity.
In conclusion, the free amino acid form of 3-NT 
does not affect the measurement of protein-bound 
3-NT. Furthermore, the influence of salivary 
contamination on the measurement of protein-
bound 3-NT in induced sputum by means of HPLC-
ECD is very small and could be negligible.
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